Recently, FGF19 has been identified as a promising therapeutic target for diabetes, cholestatic liver disease, non-alcoholic steatohepatitis (NASH), and abnormalities of BA metabolism as a result of its remarkable pharmacological capabilities [11–14]. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.